For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Summary
Fibrinogen (factor I) is a glycoprotein in vertebrates that helps in the formation of blood clots. Fibrinogen Concentrate is used as a medicine for blood disease. Fibrinogen concentrate is a preparation of coagulation factors prepared from pooled plasma. Currently, only RiaSTAP (CSL Behring) is licensed in a number of countries for multiple indications including treating acute bleeding episodes with Hypofibrinogenemia. Other manufacturer's product are justly used in local region or countries.
This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions.
The report includes as follows:
The report provides current data, historical overview and future forecast.
The report includes an in-depth analysis of the Global market for Fibrinogen Concentrates , covering Global total and major region markets.
The data of 2017-2025 are included. All-inclusive market are given through data on sales, consumption, and prices (Global total and
By major regions).
The report provides introduction of leading Global manufacturers.
Fibrinogen Concentrates market prospects to 2025 are included (in sales, consumption and price).
Market Segment as follows:
By Region / Countries
- North America (U.S., Canada, Mexico)
- Europe (Germany, U.K., France, Italy, Russia, Spain etc)
- Asia-Pacific (China, India, Japan, Southeast Asia etc)
- South America (Brazil, Argentina etc)
- Middle East & Africa (Saudi Arabia, South Africa etc)
By Type
- Animal Fibrinogen Concentrate
- Human Fibrinogen Concentrate
By End-User / Application
- Congenital Fibrinogen Deficiency
- Surgical Procedures
By Company
- CSL Behring
- LFB